July 01, 2025 a 07:43 pm
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company stands as a prominent player in the pharmaceutical industry with a diverse portfolio of drugs addressing diabetes, cancer, and various other conditions. The company's strategic collaborations and consistent innovations offer a promising outlook. The stock's performance has shown moderate growth potential based on available fundamental analyses.
Fundamental Rating
The fundamental data for Eli Lilly indicates a balanced profile with strong returns on equity and assets, albeit affected by some debt and pricing challenges.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
The historical data highlights a consistent scoring pattern in critical areas, suggesting stability.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-07-01 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| Previous | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analyst Price Targets
Analyst estimates suggest a potentially optimistic target range, with a consensus leaning towards a 'Buy'.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1146 | $700 | $970 | $963.2 |
Analyst Sentiment
The analyst sentiment reflects a strong inclination towards buying, supported by a considerable number of buy recommendations.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 7 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Given the solid return metrics and a variety of successfully marketed products, Eli Lilly and Company appears well-positioned in the pharmaceutical sector. While the stock faces some debt and valuation challenges, the prevailing sentiment and price targets indicate possible upside potential. Collaborations with leading firms further enhance its innovative drive. Overall, Eli Lilly’s strategic initiatives and robust fundamentals suggest a balanced opportunity for investors.